The regulatory environment is constantly changing. New concerns about the safety of new medicines, and various uses for large-scale, real-world data on marketed drugs’ patient safety and efficacy, as well as, new combination and comcomitant therapies are the primary growth “drivers”.
Phase IV marketing research is a critical element of pharmaceutical marketing – enabling companies to expand existing markets, enter new markets, develop and deliver value-add messaging that differentiates their products with the competition, creating a niche position in already crowded markets. The fact is, regulators are requiring more post-marketing data from drug companies, which makes absolute sense.
Given the increasing importance of phase IV trial research, increased competition and a real need for a rapid understanding of how their drugs are performing in the real-world, it is mission critical for companies to integrate a strong web-based clinical data capture and analysis tool or “system” to help them truly understand statistical trends and patient outcomes.